Anixa Biosciences (ANIX) vs Kazia Therapeutics (KZIA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kazia Therapeutics (KZIA) has outperformed Anixa Biosciences (ANIX) over the past year, gaining 24.4% versus a loss of 41.1%. Over five years, ANIX leads with a -33.9% price change compared with -98.3% for KZIA. Kazia Therapeutics is the larger company by market cap ($102.0 million vs $100.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIX | KZIA |
|---|---|---|
| Share price | $2.90 | $8.93 |
| Market cap | $100.82M | $102.04M |
| 1-day change | -0.34% | +1.25% |
| YTD return | -7.05% | +29.61% |
| 1-year return | -41.06% | +24.37% |
| 5-year return | -33.94% | -98.30% |
| EPS (TTM) | $-0.32 | $-6.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.46 | $17.40 |
| 52-week low | $2.32 | $4.86 |
| Distance from 52-week high | -46.89% | -48.68% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +236.21% | +216.46% |
| Average volume | 302.95K | 262.41K |
| Shares outstanding | 34.76M | 11.43M |
| Employees | 4 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KZIA has outperformed ANIX by 65.4 percentage points over the past year.
About Anixa Biosciences
ANIX stock →Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Kazia Therapeutics
KZIA stock →Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
ANIX vs KZIA FAQ
Which is bigger, Anixa Biosciences or Kazia Therapeutics?
Kazia Therapeutics (KZIA) is larger, with a market capitalization of $102.04M compared with $100.82M for Anixa Biosciences (ANIX).
Which stock has performed better over the past year, ANIX or KZIA?
KZIA returned +24.37% over the past 12 months, compared with -41.06% for ANIX (price return, excluding dividends). Past performance does not predict future results.
Are Anixa Biosciences and Kazia Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.